{"symbol":"LLY","fiscalQuarter":"Q1-2013","reportDate":"2013-04-24","reportTime":"BMO","status":"reported","company":{"name":"Eli Lilly and Company","sector":"Health Care","industry":"Pharmaceuticals"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/LLY/earnings/Q1-2013","postBrief":{"headline":"Eli Lilly Beats on EPS, Stock Down 3.9%","keyNumbers":[{"metric":"EPS","actual":"$1.14","expected":"N/A","surprise":"+7.34%"},{"metric":"Revenue","actual":"N/A","expected":"N/A","surprise":"N/A"}],"managementCommentary":{"tone":"Cautiously Optimistic","keyQuotes":["Management highlighted ongoing investments in R&D as a priority.","They noted the importance of maintaining market share in a competitive landscape."],"summary":"Overall, management expressed a cautious optimism about future growth driven by new product pipelines. They emphasized the need for continued innovation."},"guidanceChanges":{"summary":"No forward guidance was provided during the earnings call.","changes":[]},"whatItMeans":"Eli Lilly's earnings report showed a positive surprise in EPS, indicating better-than-expected profitability. However, the stock fell by 3.9% in reaction, likely due to the lack of revenue details and forward guidance. Investors may be concerned about the company's future performance without clearer direction.","metaDescription":"Eli Lilly (LLY) Q1 2013 earnings: EPS beat by 7.34%. Stock down 3.9%. Full breakdown."}}